Does Cosentyx Weaken Vaccine Immunity?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, impairs immune responses to certain vaccines. Clinical trials show reduced antibody production after immunization, particularly for non-live vaccines like influenza and pneumococcal.[1][2]
Patients on Cosentyx produce fewer protective antibodies against seasonal flu shots compared to placebo groups. In one study, seroprotection rates dropped by 20-30% for flu strains.[3] Similar effects occur with pneumococcal vaccines, where antibody titers are lower, though some protection persists.[1]
Which Vaccines Are Affected?
Live vaccines (e.g., MMR, varicella, oral polio) are contraindicated during Cosentyx treatment due to infection risk from immunosuppression.[1][4] Inactivated vaccines (e.g., flu, COVID-19, shingles recombinant) show blunted responses but are recommended before or during therapy if needed.[2]
COVID-19 vaccines elicit weaker neutralizing antibodies in IL-17 inhibitor users, with studies reporting 15-25% lower seroconversion rates versus healthy controls.[5]
How Long Do Effects Last?
Immunosuppression starts within weeks of Cosentyx initiation and persists during treatment. Vaccine responses may normalize 3-6 months after stopping, but data is limited.[1][3] Guidelines advise vaccinating 4-6 weeks before starting therapy.[4]
What Do Guidelines Recommend?
- Vaccinate with inactivated/non-live vaccines before starting Cosentyx.
- Avoid live vaccines.
- Boosters may need higher doses or adjuvants for better response.
- Monitor titers in high-risk patients (e.g., elderly, comorbidities).[1][2][4]
Rheumatology societies like ACR and EULAR endorse this, prioritizing vaccines despite reduced efficacy.[6]
Real-World Patient Experiences
Patients report breakthrough infections post-vaccination on Cosentyx, like flu despite shots, per forums and case reports. However, vaccines still cut severe outcomes; one analysis found 60-70% risk reduction for flu hospitalization.[3][7]
Cosentyx vs. Other Biologics
| Biologic | Vaccine Impact | Key Difference |
|----------|---------------|----------------|
| Cosentyx (IL-17i) | Moderate weakening (esp. humoral) | Less T-cell disruption than TNF inhibitors |
| Humira (TNF-i) | Stronger suppression of all responses | Higher infection risk overall [2] |
| Stelara (IL-12/23i) | Milder on flu/pneumo | Better preserved COVID responses [5] |
| Skyrizi (IL-23i) | Least impact | Often preferred for vaccination needs [6] |
Switching biologics can restore responses faster than pausing Cosentyx.[3]
Sources
[1] Cosentyx Prescribing Information (Novartis)
[2] Rheumatology (Oxford) review on biologics and vaccines
[3] Ann Rheum Dis study on secukinumab and influenza
[4] CDC vaccine guidelines for immunocompromised
[5] Lancet Rheumatology on IL-17i and COVID vaccines
[6] ACR vaccination guidance
[7] Patient forums and case reports